Evelyn and Her Prostate Cancer; Robotic Mastectomy Warning; Brits Recall Metformin

An oncologist shares insights from conversations with a prostate cancer patient named Evelyn. (JCO Art of Oncology)

With all available beds filled because of COVID, a Florida hospital had to turn away a patient needing emergency cancer care. (CNN)

Fate Therapeutics announced positive preliminary clinical results with its natural killer cell product FT516 and its FT596 CAR T-cell product in patients with relapsed/refractory B-cell lymphoma.

The National Comprehensive Cancer Network announced support for mandatory COVID-19 vaccination for healthcare workers.

The FDA issued a safety communication about the unproven safety or efficacy of robotic-assisted surgery for mastectomy to prevent or treat breast cancer.

The agency also added a new indication for ivosidenib (Tibsovo) to include treatment of cholangiocarcinoma associated with IDH1 mutations, according to a statement from Servier Pharmaceuticals.

The Society for Immunotherapy of Cancer published a new clinical guideline on evidence-based immunotherapy for breast cancer. (Journal for ImmunoTherapy of Cancer)

Incidence of adult brain cancer has declined, but survival has not improved. (CA: A Cancer Journal for Clinicians)

Merck KGaA announced termination of a phase II trial of bintrafusp alfa plus chemotherapy for advanced biliary tract cancer after an interim data analysis suggested the trial would not meet the primary endpoint of overall survival.

A phase III trial of tisagenlecleucel (Kymriah) did not meet the primary endpoint of event-free survival as second-line treatment for primary refractory B-cell non-Hodgkin lymphoma, Novartis announced.

Men with a history of benign prostatic hyperplasia had a reduced risk of prostate cancer. (Beaumont Health, The Prostate)

Heat-activated CAR T cells destroyed solid tumors and prevented relapse in laboratory models. (Georgia Tech, Nature Biomedical Engineering)

A phase II study of oral roxadustat met the primary endpoint of improving hemoglobin levels without transfusion for patients with cancer-associated anemia, FibroGen announced.

The Institute for Clinical and Economic Review will assess the comparative effectiveness and value of two novel therapies to prevent chemotherapy-induced neutropenia.

Nine of the 20 top-selling drugs will lose patent protection over the next decade, including some blockbuster cancer drugs. (FiercePharma)

British health authorities ordered a recall of the diabetes drug metformin after laboratory studies uncovered traces of the potential cancer-causing chemical NDMA. (Tech Times)